Pamela Williamson, RAC, FRAPS, has served as Quince’s head of Regulatory Affairs since July 2023. To this role, she brings more than 30 years of global leadership experience, including a strong track record in the successful development and registration of products to treat patients with serious and life-threatening rare diseases. As a former senior executive responsible for worldwide registration of small molecules and biotechnology-derived products, her background also spans multiple therapeutic areas. In addition to her experience in Regulatory Affairs, Ms. Williamson has broad expertise in the areas of quality assurance, pharmacovigilance, health authority compliance and manufacturing operations, and she has worked extensively with representatives of the U.S. Food & Drug Administration, CHMP at the European Medicines Agency, MHRA in the U.K., TGA in Australia, PMDA in Japan, and other health authorities globally.
Prior to joining Quince, Ms. Williamson served as Senior Vice President of Global Regulatory Affairs and Patient Safety at Alexion Pharmaceuticals where she was responsible for the global registration of late-stage internal research and development and external business development efforts. Prior to joining Alexion, she held senior leadership positions at Genzyme Corporation, including Senior Vice President, Global Head, Regulatory Affairs and Compliance. Prior to joining Genzyme, Ms. Williamson held several positions with Serono and Ares-Serono where she directed numerous cross-functional, multilevel development teams.
Ms. Williamson is a member of the board of trustees for the Albany College of Pharmacy and Health Sciences, the Pharmaceutical Research and Manufacturers of America, Biotechnology Industry Organization, Massachusetts Biotechnology Council, Food and Drug Law Institute, Drug Information Association, and Regulatory Affairs Professionals Society (Fellow). She holds an M.B.A. from Northeastern University in Boston.